Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 325-329 , April 2007

Effective specific activities determined by scintillation proximity counting for production runs of [18F]FES and 4F-M[18F]FES

Received 29 September 2006 ,Revised 1 December 2006 ,Accepted 2 January 2007.

References 

  1. Katzenellenbogen JA. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med. 1995;36:8S–13S
  2. Cummins CH. Radiolabeled steroidal estrogens in cancer research. Steroids. 1993;58:245–259
  3. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med. 1998;28:290–302
  4. Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med. 1998;42:8–17
  5. Seimbille Y, Rousseau J, Benard F, Morin C, Ali H, Avvakumov G, et al. 18F-Labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids. 2002;67:765–775
  6. Seimbille Y, Benard F, Rousseau J, Pepin E, Aliaga A, Tessier G, et al. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16[alpha]-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol. 2004;31:691–698
  7. Kilbourn MR, Zalutsky MR. Research and clinical potential of receptor based radiopharmaceuticals. J Nucl Med. 1985;26:655–662
  8. Katzenellenbogen JA, Heiman DF, Carlson KE, Lloyd JE. In vivo and in vitro steroids receptor assays in the design of estrogen radiopharmaceuticals. In:  Eckelman WC editors. Receptor binding radiotracers. Boca Raton (Fla): CRC Press; 1982;p. 93–126
  9. Katzenellenbogen JA, Johnson HJ, Myers HN. Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry. 1973;12:4085–4092
  10. Senderoff SG, McElvany KD, Carlson KE, Heiman DF, Katzenellenbogen JA, Welch MJ. Methodology for the synthesis and specific activity determination of 16-alpha-[77Br]-bromoestradiol-17-beta and 16-alpha-[77Br]-11-beta-methoxyestradiol-17-beta, two estrogen receptor-binding radiopharmaceuticals. Int J Appl Radiat Isot. 1982;33:545–551
  11. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212–1221
  12. Allan GF, Hutchins A, Clancy J. An ultrahigh-throughput screening assay for estrogen receptor ligands. Anal Biochem. 1999;275:243–247
  13. Levesque C, Merand Y, Dufour JM, Labrie C, Labrie F. Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem. 1991;34:1624–1630
  14. Fevig TL, Mao MK, Katzenellenbogen JA. Estrogen receptor binding tolerance of 16 alpha-substituted estradiol derivatives. Steroids. 1988;51:471–497
  15. McGuire AH, Dehdashti F, Siegel BA, Lyss AP, Brodack JW, Mathias CJ, et al. Positron tomographic assessment of 16-alpha-[18F]fluoro-17-beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526–1531
  16. Heiman DF, Senderoff SG, Katzenellenbogen JA, Neeley RJ. Estrogen receptor based imaging agents: 1. Synthesis and receptor binding affinity of some aromatic and D-ring halogenated estrogens. J Med Chem. 1980;23:994–1002

PII: S0969-8051(07)00008-X

doi: 10.1016/j.nucmedbio.2007.01.001

Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 325-329 , April 2007

Article Tools

* Image Usage & Resolution